Rashmi R. Shah

Drug‐induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity

Rashmi R. Shah · Fundamental and Clinical Pharmacology · 2002 · 77 citations

Drug Safety, Molecular Pharmacology, Health Policy +15

The Cost-Effectiveness of Drug Regulation: The Example of Thorough QT/QTc Studies

Jacoline C. Bouvy, Marc Koopmanschap, Rashmi R. Shah et al. · Clinical Pharmacology & Therapeutics · 2011 · 76 citations

Drug‐Induced QT Interval Prolongation—Regulatory Guidance and Perspectives on hERG Channel Studies

Rashmi R. Shah · Novartis Foundation symposium · 2005 · 65 citations

Lead Compounds, Molecular Pharmacology, Translational Medicine +15

Drug induced shortening of the QT/QTc interval: An emerging safety issue warranting further modelling and evaluation in drug research and development?

Mark Holbrook, Marek Malík, Rashmi R. Shah et al. · Journal of Pharmacological and Toxicological Methods · 2008 · 48 citations

Drug Safety, Safety Issue, Preclinical Drug Evaluation +9

RTN4 Knockdown Dysregulates the AKT Pathway, Destabilizes the Cytoskeleton, and Enhances Paclitaxel-Induced Cytotoxicity in Cancers

Gopal P. Pathak, Rashmi R. Shah, Barry E. Kennedy et al. · Molecular Therapy · 2018 · 47 citations · Full text